Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacology of Artemether/Lumefantrine with Nevirapine in HIV/Malaria Co-infected Children
NCT01728961Phase 4Terminated
- Sponsor
- IMPAACT Network
- Start
- Feb 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of artemether + lumefantrine in malaria (2 arms), sponsored by IMPAACT Network. Primary endpoints: Area under the curve from time zero to last quantifiable concentration at Day 14, Toxicity at Day 42 and 2 more. Started Feb 2012; status: terminated.
02
Drugs
artemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT01728961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728961.